ICF: kEtamine for the treatment of DEpression with anorexia Nervosa (EDEN)
ICF:kEtamine 用于治疗抑郁症伴神经性厌食症 (EDEN)
基本信息
- 批准号:MR/Y019504/1
- 负责人:
- 金额:$ 193.32万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2024
- 资助国家:英国
- 起止时间:2024 至 无数据
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Anorexia nervosa is a restrictive eating disorder that has a high rate of death. Approximately a third of people develop a persisting form of illness, which is often accompanied by depression, which is a barrier to recovery. Anti-depressant medications are not effective in treating depression in patients with chronic anorexia and new treatments are needed.Ketamine is currently used for the treatment of depression in the UK and may be effective in patients with AN and additional depression. The hope for this study is that people with both, anorexia, and depression, will experience relief from depression and thus get back their hope for improvement, motivation, and strength to fight their anorexia.The EDEN project aims to investigate the effect of ketamine in alleviating depression in 60 adults with a diagnosis of persisting anorexia and treatment-resistant depression. Participants in the study will randomly receive either ketamine, or a dummy pill, twice a week for a total of six months. To verify that the drug is tolerable, the first four doses will be given in the Clinical Research Facility at King's College London, where participants will be monitored by medical professionals. After this point, and if the drug is tolerated well, participants can take the drug home. All participants will also receive ten "psychoeducation and integration" sessions which are designed to increase the beneficial effects of ketamine. The main outcome will be looking at whether a sufficient number of people were recruited into the study and did not drop out over the duration of the study period, and whether people found the drug, as well as taking part in the study itself, acceptable. Measurements of depression, anorexia symptoms, suicidality, and quality of life will be taken after 28 days, and 3-, 6- and 7 months. Blood samples will also be taken in order to look at levels of ketamine.
神经性厌食症是一种限制性饮食障碍,死亡率很高。大约三分之一的人患上了一种顽固性疾病,这种疾病经常伴随着抑郁症,这是康复的障碍。抗抑郁药物对慢性厌食症患者的抑郁症治疗无效,需要新的治疗方法。目前,氯胺酮在英国用于治疗抑郁症,对患有抑郁症和其他抑郁症的患者可能有效。这项研究的希望是同时患有厌食症和抑郁症的人将从抑郁中得到缓解,从而找回改善的希望、动力和力量来对抗他们的厌食症。伊甸园项目旨在调查氯胺酮对60名被诊断为持续性厌食症和难治性抑郁症的成年人的缓解抑郁的效果。这项研究的参与者将随机接受氯胺酮或虚拟药丸,每周两次,总共持续六个月。为了验证这种药物是可耐受的,前四剂将在伦敦国王学院的临床研究设施中进行注射,参与者将在那里接受医疗专业人员的监测。在此之后,如果药物耐受性良好,参与者可以将药物带回家。所有参与者还将接受十次旨在增加氯胺酮有益效果的心理教育和融合课程。主要结果将是观察是否有足够数量的人被招募到研究中,并且在研究期间没有退出,以及人们发现药物以及参与研究本身是否可以接受。抑郁、厌食症状、自杀倾向和生活质量的测量将在28天后、3个月、6个月和7个月进行。血样也将被采集,以查看氯胺酮的水平。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hubertus Himmerich其他文献
Kompendium der Psychiatrischen Pharmakotherapie
精神科药物治疗手册
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:0
- 作者:
Hubertus Himmerich - 通讯作者:
Hubertus Himmerich
Johann Christian August Heinroth (1773–1843): The First Professor of Psychiatry as a Psychotherapist
约翰·克里斯蒂安·奥古斯特·海因罗特(1773–1843):第一位作为心理治疗师的精神病学教授
- DOI:
10.1007/s10943-011-9562-9 - 发表时间:
2012-02-02 - 期刊:
- 影响因子:2.000
- 作者:
Holger Steinberg;Hubertus Himmerich - 通讯作者:
Hubertus Himmerich
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases
- DOI:
10.1007/s40263-024-01111-1 - 发表时间:
2024-08-03 - 期刊:
- 影响因子:7.400
- 作者:
Hubertus Himmerich;Jessica Bentley;Susan L. McElroy - 通讯作者:
Susan L. McElroy
Arginine vasopressin and adrenocorticotropin secretion in response to psychosocial stress is attenuated by ethanol in sons of alcohol-dependent fathers.
在酒精依赖的父亲的儿子中,乙醇会减弱对社会心理压力做出反应的精氨酸加压素和促肾上腺皮质激素的分泌。
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:4.8
- 作者:
Ulrich S. Zimmermann;K. Spring;H. Wittchen;Hubertus Himmerich;Rainer Landgraf;M. Uhr;Florian Holsboer - 通讯作者:
Florian Holsboer
A feasibility trial of olanzapine for young people with Anorexia Nervosa (OPEN): clinicians’ perspectives
- DOI:
10.1186/s40337-024-01106-9 - 发表时间:
2024-09-27 - 期刊:
- 影响因子:4.500
- 作者:
Vanessa Kellermann;Ece Sengun Filiz;Olena Said;Jessica Bentley;Joel W.T. Khor;Mima Simic;Dasha Nicholls;Janet Treasure;Ulrike Schmidt;Hubertus Himmerich;Vanessa Lawrence - 通讯作者:
Vanessa Lawrence
Hubertus Himmerich的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Mechanisms of Low-Dose Ketamine Treatment for Parkinson's Disease [Diversity Supplement for Raveena Parmar]
低剂量氯胺酮治疗帕金森病的机制 [Raveena Parmar 的多样性补充]
- 批准号:
10740600 - 财政年份:2023
- 资助金额:
$ 193.32万 - 项目类别:
Epitranscriptomic mechanisms of the antidepressant response to ketamine in human neurons
人类神经元抗抑郁反应的表观转录组机制
- 批准号:
10607430 - 财政年份:2023
- 资助金额:
$ 193.32万 - 项目类别:
Using Ketamine to enhance memory reconsolidation and extinction of overgeneralized fear in individuals diagnosed with PTSD
使用氯胺酮增强被诊断患有创伤后应激障碍 (PTSD) 的患者的记忆重新巩固和过度恐惧的消除
- 批准号:
10574049 - 财政年份:2023
- 资助金额:
$ 193.32万 - 项目类别:
Verification of the efficacy of ketamine for treatment-resistant depression and elucidation of the mechanism of its therapeutic effect
验证氯胺酮治疗难治性抑郁症的疗效并阐明其治疗作用机制
- 批准号:
23KJ1898 - 财政年份:2023
- 资助金额:
$ 193.32万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Long-acting injectable ketamine for improved substance use disorder (SUD) treatment without dissociative effects.
长效注射氯胺酮,用于改善物质使用障碍 (SUD) 治疗,且不会产生解离效应。
- 批准号:
10744308 - 财政年份:2023
- 资助金额:
$ 193.32万 - 项目类别:
AMPA Receptor Components of the Antidepressant Response to Ketamine in Humans
人类抗抑郁药对氯胺酮反应的 AMPA 受体成分
- 批准号:
10734845 - 财政年份:2023
- 资助金额:
$ 193.32万 - 项目类别:
Intravenous Ketamine versus Personalized Accelerated Brain Stimulation in Treatment-Resistant Depression: A Pilot Randomized Feasibility Trial of Rapid-Acting Treatments (IKARE-TRD)
静脉注射氯胺酮与个性化加速脑刺激治疗难治性抑郁症:快速起效治疗的随机试点可行性试验 (IKARE-TRD)
- 批准号:
490031 - 财政年份:2023
- 资助金额:
$ 193.32万 - 项目类别:
Operating Grants
Ketamine for the treatment for opioid use disorder and suicidal ideation in the emergency department
氯胺酮用于治疗急诊科阿片类药物使用障碍和自杀意念
- 批准号:
10646993 - 财政年份:2023
- 资助金额:
$ 193.32万 - 项目类别:
Glutamatergic adaptation to stress as a mechanism for anhedonia and treatment response with ketamine
谷氨酸对压力的适应是快感缺失和氯胺酮治疗反应的机制
- 批准号:
10375849 - 财政年份:2022
- 资助金额:
$ 193.32万 - 项目类别:
Repeated Ketamine Infusions for Cognitive Impairment in Treatment-Resistant Bipolar Depression
反复输注氯胺酮治疗难治性双相抑郁症的认知障碍
- 批准号:
486443 - 财政年份:2022
- 资助金额:
$ 193.32万 - 项目类别:
Studentship Programs